Skip to content

OncoDNA

Active
Public limited companyfounded 201213 yrs activeRue Louis Breguet 1, 6041 Charleroi, BelgiumKBO/BCE: BE 0501.631.837
Summary

OncoDNA has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-257k) and a net result of €-3.79M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 6% of 637 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Checked score

Score 2025
44 / 100
Weak
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Negative equity caps the score. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency20▼-12
Growth32▼-20
Track record100
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity tight (current ratio 1.02 against 0.69 in 2024; short-term debt: 38.6% and cash: 9.9% of total assets), and equity is negative.
Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-4.9%
Return on assets
-72%
Age of the figures
9 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 13 years 0 20 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €-257k
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-07-2026, 17 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
17 d early
2024
1 d early
2023
8 d early
2022
26 d early
2021
39 d early
2020
40 d early
2019
29 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-3.79M▲ 26.3%
2024 · €-5.14M
2018: €-3.28M 2019: €-3.14M 2020: €-5.41M 2021: €-5.26M 2022: €-6.14M 2023: €-10.36M 2024: €-5.14M
2018 → 2025
Working capital
€39k
2024 · €-2.11M
2018: €-450k 2019: €2.31M 2020: €7.00M 2021: €3.91M 2022: €-2.90M 2023: €-1.24M 2024: €-2.11M
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€16.60M-€10.00M▼ 39.8%€5.84M▼ 41.6%€756k▼ 87.0%€-257k
Operating result€-4.18M-€-6.40M▼ 53.1%€-5.11M▲ 20.2%€-3.55M▲ 30.5%€-2.12M▲ 40.3%
Net result€-5.26M-€-6.14M▼ 16.8%€-10.36M▼ 68.8%€-5.14M▲ 50.4%€-3.79M▲ 26.3%
Result per fiscal year
Operating resultNet result
€-15.00M€-10.00M€-5.00M€0Operating result 2021: €-4.18M€-4.18MNet result 2021: €-5.26M€-5.26MOperating result 2022: €-6.40M€-6.40MNet result 2022: €-6.14M€-6.14MOperating result 2023: €-5.11M€-5.11MNet result 2023: €-10.36M€-10.36MOperating result 2024: €-3.55M€-3.55MNet result 2024: €-5.14M€-5.14MOperating result 2025: €-2.12M€-2.12MNet result 2025: €-3.79M€-3.79M20212022202320242025€-15M€-10M€-5M€0Operating result 2023: €-5.11M€-5.1MNet result 2023: €-10.36M€-10MOperating result 2024: €-3.55M€-3.5MNet result 2024: €-5.14M€-5.1MOperating result 2025: €-2.12M€-2.1MNet result 2025: €-3.79M€-3.8M202320242025
The operating result stays negative: a loss of €2.12M in 2025 against €3.55M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €5.23M
Fixed assets €3.16M ▼ 51.9%
Current assets €2.07M ▼ 56.5%
Key figures and ratios
2025 value · change against 2024
EBITDA
€-551k
2024 · €-1.93M
Cash flow
€-2.22M
2024 · €-3.52M
Solvency
-4.9%
2024 · 6.6%
Current ratio
1.02
2024 · 0.69
Quick ratio
0.95
2024 · 0.68
Debt to equity
-21.53
2024 · 13.93
ROA
-72.0%
2024 · -45.2%
Interest coverage
-1.80
2024 · -4.58
Debt
€5.53M
2024 · €10.52M
Debt ≤ 1 year
€2.03M
2024 · €6.87M
Debt > 1 year
€3.41M
2024 · €3.42M
Income taxes
€4k
2024 · €15k
Staff costs
€2.37M
2024 · €2.56M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 64 lines
Balance sheet Code20242025
Assets
Total assets20/58€11.39M€5.27M
Formation expenses20€63k€42k
Fixed assets21/28€6.56M€3.16M
Intangible fixed assets21€3.79M€2.30M
Tangible fixed assets22/27€25k€6k
Plant, machinery and equipment23€15k€614
Furniture and vehicles24€8k€6k
Other tangible fixed assets26€2k-
Financial fixed assets28€2.74M€846k
Current assets29/58€4.76M€2.07M
Stocks and contracts in progress3€120k€144k
Stocks30/36€120k€144k
Amounts receivable within one year40/41€1.80M€1.37M
Trade receivables40€1.72M€1.09M
Other amounts receivable41€75k€282k
Current investments50/53€1.70M-
Cash at bank and in hand54/58€1.06M€521k
Deferred charges and accrued income490/1€82k€39k
Equity and liabilities
Total equity and liabilities10/49€11.39M€5.27M
Equity10/15€756k€-257k
Contributions10/11€14.79M€4.33M
Capital10€14.79M€1.60M
Issued capital100€14.79M€1.60M
Outside capital11-€2.72M
Share premium1100/10-€2.72M
Profit (loss) carried forward14€-15.51M€-5.62M
Investment grants15€1.47M€1.03M
Provisions and deferred taxes16€107k-
Provisions for liabilities and charges160/5€107k-
Other liabilities and charges164/5€107k-
Amounts payable17/49€10.52M€5.53M
Amounts payable after more than one year17€3.42M€3.41M
Financial debts170/4€3.42M€3.41M
Amounts payable within one year42/48€6.87M€2.03M
Current portion of amounts payable after more than one year42€4.14M€288k
Financial debts43€51k-
Credit institutions430/8€51k-
Trade debts44€1.89M€1.29M
Suppliers440/4€1.89M€1.29M
Taxes, remuneration and social security45€495k€346k
Taxes450/3€3k€4k
Remuneration and social security454/9€492k€342k
Other amounts payable47/48€292k€108k
Accrued charges and deferred income492/3€230k€82k
Income statement Code20242025
Remuneration, social security and pensions62€2.56M€2.37M
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.62M€1.57M
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€45k€66k
Provisions for liabilities and charges: additions (uses and reversals)635/8€41k€-107k
Other operating charges640/8€490k€305k
Non-recurring operating charges66A-€103
Gross operating margin9900€1.21M€2.08M
Operating profit (loss)9901€-3.55M€-2.12M
Financial income75/76B€617k€531k
Recurring financial income75€617k€531k
Financial charges65/66B€2.20M€2.20M
Recurring financial charges65€421k€306k
Non-recurring financial charges66B€1.78M€1.90M
Profit (loss) for the period before taxes9903€-5.13M€-3.79M
Income taxes67/77€15k€4k
Profit (loss) for the period9904€-5.14M€-3.79M
Profit (loss) for the period to be appropriated9905€-5.14M€-3.79M
Appropriation of the result
Profit (loss) to be appropriated9906€-15.51M€-5.62M
Profit (loss) brought forward from the previous period14P€-10.36M€-1.82M
Social balance
Average headcount (FTE)908722.020.6

The notes to these accounts (25 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
29-07
State Gazette act Reappointments: Société Fédérale de Participations et d'Investissement, An Herremans and 3 others
Permanent representatives: François Fontaine and Guy Geldhof · Mandate compensation · Power of attorney10 facts ▸
  • General meeting, 17/06/2026
  • Director reappointment, Société Fédérale de Participations et d'Investissement (director)
  • Director reappointment, An Herremans (director)
  • Director reappointment, Geldhof Enterprises (director)
  • Director reappointment, François Blondel (director)
  • Director reappointment, Charles-André Brouwers (director)
  • Permanent representative, François Fontaine
  • Permanent representative, Guy Geldhof
  • Mandate compensation, Société Fédérale de Participations et d'Investissement
  • Power of attorney, Charles-André Brouwers
14-07
NBB filing Annual accounts filed
fiscal year 2025 · full schema
17-06
State Gazette act Reappointment: Deloitte Réviseurs d'Entreprises (statutory auditor)
2 facts ▸
  • General meeting, 18-07-2025
  • Auditor reappointment, Deloitte Réviseurs d'Entreprises
2025
30-07
NBB filing Annual accounts filed
fiscal year 2024 · full schema
18-04
State Gazette act Capital & shares · Statutes amendment
Capital decrease · Capital increase · Capital7 facts ▸
  • General meeting, 28-03-2025
  • Capital decrease, €13.683.878,26
  • Capital increase, €500.000
  • Capital increase, €15
  • Capital, €1.604.352,01
  • Statutes amendment
  • Power of attorney, Osborne Clarke
2024
20-08
State Gazette act Resignation: William E. Rhodes, III (director)
2 facts ▸
  • General meeting, 28-07-2024
  • Director resignation, William E. Rhodes, III (director)
23-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
20-06
State Gazette act Resignation: Bernard Courtieu (directeur général)
Appointment: Finadec SRL (directeur financier) · Power of attorney · Mandate compensation18 facts ▸
  • Board meeting, 04-04-2024
  • Director resignation, Bernard Courtieu (directeur général (chief executive officer))
  • Power of attorney, Bernard Courtieu
  • Director appointment, Finadec SRL (directeur financier (chief financial officer))
  • Power of attorney, Finadec SRL
  • Board composition, Ignis Consulting SARL (chief strategy and innovation officer (csio))
  • Board composition, Finadec SRL (directeur financier (cfo))
  • Board composition, Wakari SRL (chief infomation officer (cio))
  • Board composition, Koenraad Eycken (chief product officer (cpo))
  • Board composition, MP HR Consulting SCs (head of hr)
  • Board composition, Gontran Brichard (qa)
  • Board composition, Adriana Terradez (head of sales)
  • +6 further facts in this act
2023
31-12
Financial Weakest financial yearnet €-10.36M
Net result drops to €-10.36M, the lowest in the series; recovery starts the following year.
05-07
NBB filing Annual accounts filed
fiscal year 2022 · full schema
26-06
State Gazette act Capital & shares
Approval · Director discharge · Capital decrease11 facts ▸
  • General meeting, 20-06-2023
  • Approval, 31-12-2022
  • Director discharge, OncoDNA (director)
  • Director discharge, Deloitte Réviseurs d'Entreprises SRL (statutory auditor)
  • Capital decrease, €22.330.494,74
  • Capital increase, €6.659.305,56
  • Capital increase, €25
  • Share issue, Warrants Anti-Dilutifs, 15
  • Statutes amendment
  • Share class reorganization, actions préférentielles de classe C
  • No dissolution, actif net réduit à un montant inférieur à la moitié du capital, article 7:228 du Code des sociétés et des associations
55% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
16-06
State Gazette act Resignations: Alain Declercq, Swisscanto (CH) Private Equity Switzerland Growth I KmGK and 8 others
Appointments: Société Fédérale de Participations et d'Investissement, An Herremans and 4 others · Permanent representatives: Robert Schier, Jean Stéphenne and 2 others21 facts ▸
  • General meeting, 17/05/2023
  • Director resignation, Alain Declercq (director)
  • Director resignation, Swisscanto (CH) Private Equity Switzerland Growth I KmGK (director)
  • Director resignation, Innoste (director)
  • Director resignation, Jean-Pol Detiffe (director)
  • Director resignation, Société Fédérale de Participations et d'Investissement (director)
  • Director resignation, An Herremans (director)
  • Director resignation, Geldhof Enterprises (director)
  • Director resignation, François Blondel (director)
  • Director resignation, William R. "Bill" Rhodes (director)
  • Director resignation, Charles-André Brouwers (director)
  • Director appointment, Société Fédérale de Participations et d'Investissement (director)
  • +9 further facts in this act
Show earlier events
2022
28-07
State Gazette act Resignation: Synneo SRL (member of the executive committee)
Appointment: Koenraad Eycken (member of the executive committee)3 facts ▸
  • Board meeting, 28-04-2022
  • Director resignation, Synneo SRL (member of the executive committee)
  • Director appointment, Koenraad Eycken (member of the executive committee)
23-06
State Gazette act Reappointments: Deloitte Réviseurs d'Entreprises SRL, Jean-Pol Detiffe and 9 others
Permanent representatives: Guy Geldhof, Robert Schier and 2 others16 facts ▸
  • General meeting, 02-06-2022
  • Auditor reappointment, Deloitte Réviseurs d'Entreprises SRL
  • Director reappointment, Jean-Pol Detiffe (director)
  • Director reappointment, François Blondel (director)
  • Director reappointment, Alain Declercq (director)
  • Director reappointment, An Herremans (director)
  • Director reappointment, Charles-André Brouwers (director)
  • Director reappointment, William R. "Bill" Rhodes (director)
  • Director reappointment, Geldhof Enterprises (director)
  • Permanent representative, Guy Geldhof
  • Director reappointment, Swisscanto (CH) Private Equity Switzerland Growth I KmGK (director)
  • Permanent representative, Robert Schier
  • +4 further facts in this act
22-06
NBB filing Annual accounts filed
fiscal year 2021 · full schema
2021
09-08
State Gazette act Resignations: INVENTURES, BIO.BE and John-Eric BERTRAND
Appointments: Charles-André BROUWERS, William R. "Bill" RHODES and 4 others · Permanent representatives: Olivier DE DUVE and Jean-François GHIDETTI · Capital increase17 facts ▸
  • General meeting, 02-07-2021
  • Capital increase, €500.000
  • Bank account, BE75 3632 1274 1551
  • Capital, €30.459.379,45
  • Director resignation, INVENTURES (director)
  • Director resignation, BIO.BE (director)
  • Director resignation, John-Eric BERTRAND (director)
  • Director appointment, Charles-André BROUWERS (independent director)
  • Director appointment, William R. "Bill" RHODES (independent director)
  • Director appointment, An HERREMANS (director)
  • Director appointment, INVENTURES (observateur)
  • Director appointment, BIO.BE (observateur)
  • +5 further facts in this act
15-07
State Gazette act Resignation: Ignis Consulting SARL (directeur général)
Appointment: Bernard Courtieu (directeur général) · Power of attorney · Power-of-attorney revocation14 facts ▸
  • Board meeting, 12-04-2021
  • Director resignation, Ignis Consulting SARL (directeur général (chief executive officer))
  • Director appointment, Bernard Courtieu (directeur général (chief executive officer))
  • Board composition, Bernard Courtieu (chief executive officer (ceo))
  • Board composition, Ignis Consulting SARL (chief strategy and innovation officer (csio))
  • Board composition, Ardeam SRL (chief financial officer (cfo))
  • Board composition, Bérengère Génin (head of academics / research business unit)
  • Board composition, Emmanuel Martin (chief operation officer (coo))
  • Board composition, Synneo SRL (chief product officer (cpo))
  • Power of attorney, Ardeam SRL
  • Power-of-attorney revocation, Révocation de tous les pouvoirs précédemment accordés au comité exécutif dans le cadre de la gestion journalière par les décisions du conseil d'administration d…
  • Board committee powers, Le comité de nomination et de rémunération (RemCo) a le pouvoir d'engager et licencier les employés, de déterminer leurs fonctions, conditions d'emploi et de pr…
  • +2 further facts in this act
21-06
NBB filing Annual accounts filed
fiscal year 2020 · full schema
18-01
State Gazette act Resignations: Jean Stéphenne (director) and SAMBRINVEST SPIN-OFF/SPIN-OUT (director)
Appointments: Innoste SA, Alain Declercq and Société Fédérale de Participations et d'Investissement - Federale Participatie - en Investeringsmaatschappij · Permanent representatives: Jean Stéphenne and François Fontaine · Capital increase15 facts ▸
  • General meeting, 23-12-2020
  • Capital increase, €8.488.910
  • Capital increase, €294.000
  • Bank account, IBAN BE70 3632 0691 8925
  • Share issue, Warrants Anti-Dilutifs, 15
  • Capital, €29.959.379,45
  • Director resignation, Jean Stéphenne (director)
  • Director appointment, Innoste SA (director)
  • Permanent representative, Jean Stéphenne
  • Director resignation, SAMBRINVEST SPIN-OFF/SPIN-OUT (director)
  • Director appointment, Alain Declercq (non-statutory director)
  • Director appointment, Société Fédérale de Participations et d'Investissement - Federale Participatie - en Investeringsmaatschappij (non-statutory director)
  • +3 further facts in this act
2020
31-12
Financial Equity above €10MEq €15.91M ▲252%
Equity rises from €4.52M to €15.91M.
10-11
State Gazette act Resignation: Jean Stéphenne (director and chair of the board)
Appointment: Innoste SA (director) · Permanent representative: Jean Stéphenne5 facts ▸
  • Board meeting, 2020
  • Director resignation, Jean Stéphenne (director and chair of the board)
  • Director appointment, Innoste SA (director)
  • Director appointment, Innoste SA (chair of the board)
  • Permanent representative, Jean Stéphenne
02-07
NBB filing Annual accounts filed
fiscal year 2019 · full schema
14-04
State Gazette act Capital & shares · Statutes amendment
Share issue · Capital increase · Bank account31 facts ▸
  • General meeting, 12-03-2020
  • Share issue, Droits de Souscription, 475000
  • Capital increase, €3.825.006,25
  • Bank account, ING Belgique, BE62 3631 9751 3561
  • Share cancellation, Droits de Souscription (Warrants Anti-Dilutifs), 12
  • Share issue, Warrants Anti-Dilutifs, 15
  • Capital, €21.176.469,45
  • Statutes amendment
  • Power of attorney, Pierre FLAMANT
  • Power of attorney, Pierre FLAMANT
  • Power of attorney, Pierre FLAMANT
  • Power of attorney, Pierre FLAMANT
  • +19 further facts in this act
05-03
State Gazette act Appointment: Swisscanto (CH) Private Equity Switzerland Growth I KmGK (non-statutory director)
Permanent representative: Robert Schier · Capital increase · Bank account15 facts ▸
  • General meeting, 07-02-2020
  • Capital increase, €7.129.350
  • Bank account, IBAN BE62 3631 9751 3561
  • Share issue, warrants, 12
  • Statutes amendment
  • Capital, €17.351.463,2
  • Director appointment, Swisscanto (CH) Private Equity Switzerland Growth I KmGK (non-statutory director)
  • Permanent representative, Robert Schier
  • Mandate compensation, Swisscanto (CH) Private Equity Switzerland Growth I KmGK
  • Warrant cancellation, 11, 25-11-2019
  • Statutes amendment
  • Statutes amendment
  • +3 further facts in this act
2019
31-12
Financial Liquidity doublescurrent ratio 1.90
Current ratio from 0.87 to 1.90; short-term debt falls from €3.36M to €2.57M.
31-12
Financial Equity above €2MEq €4.52M ▲14644%
Equity rises from €31k to €4.52M.
20-12
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Capital · Capital increase · Bank account16 facts ▸
  • General meeting, 25-11-2019
  • Capital, €10.222.113,2
  • Capital increase, €4.000.000
  • Bank account, BE74 3631 9324 9807
  • Share issue, actions préférentielles, 640000
  • Share issue, Warrants Anti-Dilutifs, 11
  • Statutes amendment
  • Director resignation
  • Director appointment
  • Share conversion, 802670, 1:1
  • Warrant cancellation, Warrants Anti-Dilutifs, 10
  • Share category creation, actions préférentielles, convention de souscription et d'actionnaires signée en date du 23 octobre 2019
  • +4 further facts in this act
80.1% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
12-07
State Gazette act Capital & shares · Miscellaneous
Capital · Statutes amendment3 facts ▸
  • General meeting, 15-02-2019
  • Capital, €6.222.113,2
  • Statutes amendment
05-07
State Gazette act Reappointment: Deloitte Réviseurs d'Entreprises SCRL (statutory auditor)
2 facts ▸
  • General meeting, 18-06-2019
  • Auditor reappointment, Deloitte Réviseurs d'Entreprises SCRL
05-07
NBB filing Annual accounts filed
fiscal year 2018 · full schema
12-03
State Gazette act Appointment: Société Fédérale de Participations et d'Investissement - Federale Participatie- en Investeringsmaatschappij (director)
Capital increase · Share issue · Capital8 facts ▸
  • General meeting, 15-02-2019
  • Capital increase, €2.605.583,2
  • Capital increase, €2.525.000
  • Share issue, warrants anti dilutifs, 10
  • Capital, €8.747.113,2
  • Statutes amendment
  • Director appointment, Société Fédérale de Participations et d'Investissement - Federale Participatie- en Investeringsmaatschappij (director)
  • Mandate compensation, Société Fédérale de Participations et d'Investissement - Federale Participatie- en Investeringsmaatschappij
2018
04-07
State Gazette act Appointments: Jean-Pol Detiffe, Pierre Flamant and 3 others
Mandate compensation · Power of attorney · Confirmation14 facts ▸
  • Board meeting, 08-05-2018
  • Board composition, Ignis Counsulting SARL (member of the executive committee)
  • Board composition, Ardeam SPRL (member of the executive committee)
  • Board composition, Jean-François Laes (member of the executive committee)
  • Board composition, Grégori Ghitti (member of the executive committee)
  • Board composition, Michelle Meijer (member of the executive committee)
  • Mandate compensation, ONCODNA
  • Power of attorney, Ardeam SPRL
  • Director appointment, Jean-Pol Detiffe (directeur général)
  • Director appointment, Pierre Flamant (cfo)
  • Director appointment, Jean-François Laes (cto)
  • Director appointment, Grégori Ghitti (it director)
  • +2 further facts in this act
21-06
NBB filing Annual accounts filed
fiscal year 2017 · full schema
01-06
State Gazette act Reappointment: INVENTURES (director)
Net-asset statement · Capital decrease · Capital8 facts ▸
  • General meeting, 28-05-2018
  • Net-asset statement, 31-03-2018
  • Capital decrease, €7.696.851,58
  • Capital, €1.205.397,92
  • Statutes amendment
  • Power of attorney, Philippe DUPUIS
  • Director reappointment, INVENTURES (director)
  • Power of attorney, ONCODNA
2017
06-06
NBB filing Annual accounts filed
fiscal year 2016 · full schema
05-05
State Gazette act Appointments: Ignis Counsulting SARL, Jean-François Laes and Pierre Flamant
Mandate compensation · Power of attorney · Registered-office move9 facts ▸
  • Board meeting, 06-02-2017
  • Director appointment, Ignis Counsulting SARL (member of the executive committee)
  • Director appointment, Jean-François Laes (member of the executive committee)
  • Director appointment, Pierre Flamant (member of the executive committee)
  • Mandate compensation, Ignis Counsulting SARL
  • Mandate compensation, Jean-François Laes
  • Mandate compensation, Pierre Flamant
  • Power of attorney, Pierre Flamant
  • Registered-office move, 6041 Charleroi, avenue Louis Breguet 1
09-03
State Gazette act Appointment: INVENTURES (director)
Permanent representative: Olivier de DUVE · Share issue · Capital increase14 facts ▸
  • General meeting, 16-02-2017
  • Share issue, Droits de Souscription, 113582
  • Capital increase, €43.750,6
  • Capital increase, €49.997,4
  • Capital increase
  • Capital, €8.902.249,5
  • Registered-office move, 6041 Charleroi (Gosselies), Avenue Louis Breguet, 1
  • Board meeting, 06-02-2017
  • Director appointment, INVENTURES (director)
  • Permanent representative, Olivier de DUVE
  • Mandate compensation, INVENTURES
  • Power of attorney, Conseil d'Administration
  • +2 further facts in this act
2016
01-12
State Gazette act Appointment: Deloitte Réviseurs d'Entreprises SC s.f.d. SCRL (statutory auditor)
Mandate compensation3 facts ▸
  • General meeting, 16-11-2016
  • Auditor appointment, Deloitte Réviseurs d'Entreprises SC s.f.d. SCRL (statutory auditor)
  • Mandate compensation, Deloitte Réviseurs d'Entreprises SC s.f.d. SCRL
23-09
State Gazette act Resignations: AMNASSEN SPRL (chair of the board) and Jean-Pol DETIFFE (managing director)
Appointments: Jean STEPHENNE (chair of the board) and IGNIS CONSULTING SARL (daily management delegate) · Permanent representative: Jean-Pol DETIFFE · Power of attorney8 facts ▸
  • Board meeting, 01-09-2016
  • Director resignation, AMNASSEN SPRL (chair of the board)
  • Director appointment, Jean STEPHENNE (chair of the board)
  • Director resignation, Jean-Pol DETIFFE (managing director)
  • Director appointment, IGNIS CONSULTING SARL (daily management delegate)
  • Permanent representative, Jean-Pol DETIFFE
  • Power of attorney, Fieldfisher (Belgium) LLP
  • Power of attorney, Corpoconsult Sprl
16-09
State Gazette act Appointments: John-Eric BERTRAND, SPARAXIS and 5 others
Permanent representatives: Géry LEFEBVRE, Michel PETEIN and 2 others · Capital increase · Bank account38 facts ▸
  • General meeting, 01-09-2016
  • Capital increase, €168.500,5
  • Bank account, ING BELGIQUE, BE59 3631 6369 5826
  • Statutes amendment
  • Capital increase, €7.500.001
  • Share issue, 217391, 999998.60
  • Share issue, 597826, 2749999.60
  • Share issue, 326087, 1500000.20
  • Share issue, 271739, 1249999.40
  • Share issue, 21739, 99999.40
  • Share issue, 32609, 150001.40
  • Share issue, 21739, 99999.40
  • +26 further facts in this act
01-09
State Gazette act Reappointments: AMNASSEN, Philippus JANSSENS de VAREBEKE and 5 others
Permanent representatives: François Blondel, Micheline Streel and Michel Pétein11 facts ▸
  • General meeting, 14-06-2016
  • Director reappointment, AMNASSEN (director)
  • Permanent representative, François Blondel
  • Director reappointment, Philippus JANSSENS de VAREBEKE (director)
  • Director reappointment, Sambrinvest Spin-Off/Spin-Out (director)
  • Permanent representative, Micheline Streel
  • Director reappointment, Jean-Pol DETIFFE (director)
  • Director reappointment, BIO.BE (director)
  • Permanent representative, Michel Pétein
  • Director reappointment, Jean-Michel VERHAEGEN (director)
  • Director reappointment, Jean STEPHENNE (director)
18-01
State Gazette act Capital & shares
Capital increase · Accounting effect · Capital7 facts ▸
  • General meeting, 15-12-2015
  • Capital increase, €500.000
  • Accounting effect, 01-01-2016
  • Capital, €1.140.000
  • Statutes amendment
  • Share division, 250, 37500
  • Beneficiary shares, 625000, identique aux actions existantes à la constitution de la Société
2015
13-04
State Gazette act Resignation: Pierre LEFESVRE (director)
2 facts ▸
  • Board meeting, 20-01-2015
  • Director resignation, Pierre LEFESVRE (director)
10-04
State Gazette act Miscellaneous
Share cancellation · Statutes amendment · Share attribution5 facts ▸
  • General meeting, 25-03-2015
  • Share cancellation, parts bénéficiaires, 1000
  • Statutes amendment
  • Share attribution, parts bénéficiaires, 2500
  • Share conversion, actions de catégorie A
2012
14-12
State Gazette act Incorporation
Appointments: Jean-Pol DETIFFE, Pierre LEFESVRE and 6 others · Permanent representatives: François BLONDEL, Michel PETEIN and Micheline STREEL · Founding capital22 facts ▸
  • Incorporation, 23-11-2012
  • Founding capital, €640.000
  • Bank account, ING Banque
  • General meeting, 23-11-2012
  • Director appointment, Jean-Pol DETIFFE (director)
  • Director appointment, Pierre LEFESVRE (director)
  • Director appointment, Philippe JANSSENS de VAREBEKE (director)
  • Director appointment, AMNASSEN (director)
  • Permanent representative, François BLONDEL
  • Director appointment, BIO.BE (director)
  • Permanent representative, Michel PETEIN
  • Director appointment, Jean-Michel VERHAEGEN (director)
  • +10 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
23 directors, last change in 2026
FINADEC
Directeur financier (chief financial officer) · since 06-11-2023 · Private limited company
Current
An Herremans
Director · since 17-05-2023
Current
Charles-André Brouwers
Director · since 17-05-2023
Current
François BLONDEL
Director · since 17-05-2023
Current
GELDHOF ENTERPRISES
Director · since 17-05-2023 · Private limited company · perm. rep.: Guy Geldhof
Current
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT
Director · since 17-05-2023 · Public limited company · perm. rep.: François Fontaine
Current
17 other directors
William R. "Bill" Rhodes
Director · since 17-05-2023
Current
Koenraad Eycken
Member of the executive committee · since 15-04-2022
Current
BIO.BE
Observateur · since 02-07-2021 · Public limited company · perm. rep.: Jean-François GHIDETTI
Current
INVENTURES
Observateur · since 02-07-2021 · Public limited company · perm. rep.: Olivier de DUVE
Current
Alain Declercq
Non-statutory director · since 23-12-2020
Current
Grégori Ghitti
It director · since 04-07-2018
Not recently confirmed
Jean-François Laes
Cto · since 06-02-2017
Not recently confirmed
Michelle Meijer
Sales director · since 04-07-2018
Not recently confirmed
Pierre Flamant
Cfo · since 06-02-2017
Not recently confirmed
Ignis Counsulting SARL
Member of the executive committee · since 06-02-2017 · Legal entity
Not recently confirmed
AMNASSEN
Director · since 23-11-2012 · Private limited company · perm. rep.: François BLONDEL
Not recently confirmed
BIO.BE
Director · since 01-09-2016 · Legal entity · perm. rep.: Michel PETEIN
Not recently confirmed
Sambrinvest spin-off/spin-out
Director · since 14-06-2016 · Legal entity · perm. rep.: Micheline Streel
Not recently confirmed
SPARAXIS
Director · since 01-09-2016 · Public limited company · perm. rep.: Géry LEFEBVRE
Not recently confirmed
Jean-Michel Verhaegen
Director · since 23-11-2012
Not recently confirmed
Philippus JANSSENS de VAREBEKE
Director · since 14-06-2016
Not recently confirmed
Philippe JANSSENS de VAREBEKE
Director · since 23-11-2012
Not recently confirmed
17-06-2026 An Herremans: Mandate renewed as Director
17-06-2026 Charles-André Brouwers: Mandate renewed as Director
17-06-2026 François BLONDEL: Mandate renewed as Director
17-06-2026 GELDHOF ENTERPRISES: Mandate renewed as Director
17-06-2026 SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT: Mandate renewed as Director
Full history in the Timeline (78 changes) →
Not every act has been read: a resignation may be missing here
2 acts were read only in part. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Charleroi · 1 establishment unit since 2013
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Louis Breguet 16041 Charleroi
1 establishment unit
ONCODNA
Rue Louis Breguet 1, 6041 CharleroiScientific research and development
since 20132.220.215.281

Statutory auditor

2 auditors
Deloitte Réviseurs d'EntreprisesCurrent
Auditor
02-07-2021 → present
SRL DELOITTE Réviseurs d'EntreprisesCurrent
Auditor
02-06-2022 → present
Show 2 earlier auditors
SC s.f.d. SCRL Deloitte Réviseurs d'Entreprises
Statutory auditor · represented by Julie DELFORGE
succeeded by SCRL Deloitte Réviseurs d'Entreprises in 2019
16-11-2016 → 18-06-2019
SCRL Deloitte Réviseurs d'Entreprises
Auditor
succeeded by Deloitte Réviseurs d'Entreprises in 2021
18-06-2019 → 02-07-2021

Articles of association

Who signs
“La société est valablement représentée même pour les actions en justice, par deux administrateurs et/ou par l'administrateur délégué.”
Purpose
Toute prestation généralement quelconque de biologie moléculaire et notamment d'analyse génétique de tumeurs ; la recherche, la conception, le développement, la fabrication et la…
Full purpose

Toute prestation généralement quelconque de biologie moléculaire et notamment d'analyse génétique de tumeurs ; la recherche, la conception, le développement, la fabrication et la commercialisation de tous produits ainsi que la prestation de tous services dans les domaines décrits ci-avant ; la commercialisation de procédés industriels sous quelque forme que ce soit ; la production, la promotion, l'achat et la vente, la sous-traitance, l’importation, l'exportation en gros, demi-gros ou en détail, la représentation et la maintenance dans les domaines précités ; les services professionnels, la consultance, le parrainage et le partenariat dans les objets qui précèdent ; le dépôt et l'exploitation des brevets, dessins et modèles, marques et autres droits intellectuels et patrimoniaux issus des objets qui précèdent ; la formation, l'information, la publication et l'édition sur tous supports en relation avec les objets qui précèdent ; la recherche, l'étude, la conception, l'achat et la vente de tous types d'appareillages et accessoires nécessaires à la fabrication, la transformation, la conservation et l'utilisation des produits précités.

Structure & network

Connections & network

82 connected companies
François BLONDEL, Shared director, links 8 companies FBFrançois BLONDELINNODE, via François BLONDEL IINNODEAMONIS, via François BLONDEL AAMONISCENTRE DE RESSOURCES TECHNOLOGIQUES EN CHIMIE, via François BLONDEL CDCENTRE DERESSOURCES…COMPAGNIE DU BOIS SAUVAGE, via François BLONDEL CDCOMPAGNIE DUBOIS SAUVAGECOMPAGNIE DU BOIS SAUVAGE SERVICES, via François BLONDEL CDCOMPAGNIE DUBOIS SAUVAGE…SOPARTEC, via François BLONDEL SSOPARTECSPARKOH!, via François BLONDEL SSPARKOH!Whitestone Group, via François BLONDEL WGWhitestoneGroupAn Herremans, Shared director, links 3 companies AHAn HerremansAvH Growth Capital, via An Herremans AGAvH GrowthCapitalCOMPAGNIE D'ENTREPRISES CFE, via An Herremans CDCOMPAGNIED'ENTREPRISES…Indigo Diabetes, via An Herremans IDIndigoDiabetes+32 companies via a shared corporate director +32via a sharedcorporate directorOncoDNA OncoDNA0501.631.837
Shared directorsBundled connections
Linked via shared directors
INNODE
via François BLONDEL · Permanent representative
AMONIS
via François BLONDEL · Independent director
former
Show 78 more companies with a shared director
former
former
former
former
former
former
6K venture capital
Shared director
Alfa Park
Shared director
ALURAL BELGIUM
Shared director
ASEPTIC TECHNOLOGIES
Shared director
BANK J.VAN BREDA & C°
Shared director
BESIX Group
Shared director
BIO-SOURCING
Shared director
BNP Paribas Fortis
Shared director
BPC Group
Shared director
Catalent Gosselies PS
Shared director
CinemaNext
Shared director
DELEN PRIVATE BANK
Shared director
Dematic
Shared director
Fondation Saint - Luc
Shared director
ImmunXperts
Shared director
J.MICHEL VERHAEGEN
Shared director
MEDIAHUIS
Shared director
Mediahuis Partners
Shared director
NANOCYL
Shared director
SAMBRELEASE
Shared director
SIPEF
Shared director
Virvolti
Shared director
Aphea.Bio
Shared corporate director
ASCO INDUSTRIES
Shared corporate director
Aviapartner Belgium
Shared corporate director
Banqup Group
Shared corporate director
Belgian Mobile ID
Shared corporate director
BeLightning
Shared corporate director
BioSenic
Shared corporate director
BIOXODES
Shared corporate director
CALYOS
Shared corporate director
CISSOID
Shared corporate director
COMET TRAITEMENTS
Shared corporate director
COMET TYRE RECYCLING
Shared corporate director
COMETSAMBRE
Shared corporate director
DIGITAL ATTRAXION
Shared corporate director
DREAMWALL
Shared corporate director
ELECTRAWINDS
Shared corporate director
EPICS THERAPEUTICS
Shared corporate director
EPIMEDE
Shared corporate director
Fund+
Shared corporate director
HEX - RAYS
Shared corporate director
Inbiose
Shared corporate director
LetsBuild Holding
Shared corporate director
LINEAS
Shared corporate director
LINEAS GROUP
Shared corporate director
Orizio
Shared corporate director
Palais des Congrès
Shared corporate director
Publiwind
Shared corporate director
Sabena Aerospace Engineering
Shared corporate director
SmartSec
Shared corporate director
SPARKI
Shared corporate director
THEODORUS IV
Shared corporate director
Uniteq
Shared corporate director
VIVES II - Louvain Technology Fund
Shared corporate director
ZEPHYR - FIN
Shared corporate director

Capital and shareholders

Shareholders according to the acts
After 2 capital increases act of 26-06-2023 ↗
After 2 capital increases act of 18-01-2021 ↗
After 2 capital increases act of 14-04-2020 ↗
After the capital increase act of 05-03-2020 ↗
After 2 capital increases act of 12-03-2019 ↗
After 3 capital increases act of 09-03-2017 ↗
  • BUSINESS INNOVATION S.L. 8,361 shares
  • Adriana TERRADEZ LAVERGNE 1,150 shares
  • Pierre FLAMANT 10,869 shares
Show 2 older mentions
After the capital increase act of 18-01-2016 ↗
  • Jean-Pol DETIFFE 1,953 shares
  • Michaël HERMAN 254 shares
  • Gregori GHITTI 254 shares
  • Jean-Francois LAES 469 shares
  • Invest4OncoDNA 29,297 shares
  • SCDC VINSOVIER 19,531 shares
  • Jean-Marie HENROTIN 4,883 shares
  • BIO.BE 39,062 shares
  • SAMBRINVEST SPIN-OFF/SPIN-OUT 29,297 shares
At incorporation act of 14-12-2012 ↗

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 18-04-2025 Capital reduction of 13,683,878.26 EUR · to 1,104,337.01 EUR · to absorb losses
  2. 18-04-2025 Capital increase of 500,000 EUR · to 1,604,337.01 EUR · 3,731,365 new shares · in kind
  3. 18-04-2025 Capital increase of 15 EUR · to 1,604,352.01 EUR · 6,053,627 new shares · “exercice de droits de souscription anti-dilutifs 2023”
  4. 26-06-2023 Capital reduction of 22,330,494.74 EUR · to 8,128,884.71 EUR · to absorb losses
  5. 26-06-2023 Capital increase of 6,659,305.56 EUR · to 14,788,190.27 EUR · 1,640,202 new shares
  6. 26-06-2023 Capital increase of 25 EUR · to 14,788,215.27 EUR
  7. 09-08-2021 Capital increase of 500,000 EUR · to 30,459,379.45 EUR · 80,000 new shares
  8. 18-01-2021 Capital increase of 8,488,910 EUR · to 29,665,379.45 EUR · 1,358,222 new shares
Show 14 older capital entries
  1. 18-01-2021 Capital increase of 294,000 EUR · to 29,959,379.45 EUR · 47,040 new shares
  2. 14-04-2020 Capital increase of 3,825,006.25 EUR · to 21,176,469.45 EUR · 612,001 new shares
  3. 05-03-2020 Capital increase of 7,129,350 EUR · to 17,351,463.20 EUR · 1,140,696 new shares
  4. 20-12-2019 Capital increase of 4,000,000 EUR · to 10,222,113.20 EUR · 640,000 new shares
  5. 12-07-2019 Capital stated in the act · 6,222,113.20 EUR
  6. 12-03-2019 Capital increase of 2,605,583.20 EUR · to 6,222,113.20 EUR · 398,670 new shares · in kind
  7. 12-03-2019 Capital increase of 2,525,000 EUR · to 8,747,113.20 EUR · 404,000 new shares · in cash
  8. 01-06-2018 Capital reduction of 7,696,851.58 EUR · to 1,205,397.92 EUR · to absorb losses
  9. 09-03-2017 Capital increase of 43,750.60 EUR · to 8,852,252.10 EUR · 9,511 new shares · in kind
  10. 09-03-2017 Capital increase of 49,997.40 EUR · to 8,902,249.50 EUR · 10,869 new shares · in cash
  11. 16-09-2016 Capital increase of 168,500.50 EUR · to 1,308,500.50 EUR · 240,715 new shares
  12. 16-09-2016 Capital increase of 7,500,001 EUR · to 8,808,501.50 EUR · 1,630,435 new shares
  13. 18-01-2016 Capital increase of 500,000 EUR · to 1,140,000 EUR · 125,000 new shares
  14. 14-12-2012 Incorporation · 640,000 EUR · 6,400 shares

Public money · subsidies and aid

European Union, budget

2023 · 1 entry · 121,194 EUR in total
Year Entries awarded
2023 1 121,194 EUR
Projects
DIGIONE I3 - DIGITAL INFRASTRUCTURE FOR ONCOLOGY IN EUROPE
European Regional Development Fund · 01-11-2023 to 30-04-2026 · 121,194 EUR

Recognitions · licences · registrations

Legal Entity Identifier

984500D5DAEA3C774U19
live in the LEI register

Similar companies · same sector, comparable size

Of 698 companies in sector 86910 we hold annual accounts for 520. 394 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification
Legal formPublic limited company
Founded29-11-2012
Fiscal year end31-12
Activities, NACEBEL 2025
86910Medical imaging and medical laboratories
Sources
Crossroads Bank for EnterprisesNational Bank · 13 filings

Scores and ratios are computed by Checked and are not a credit decision.

Contact details

2 entries
Enterprise
E-mail:corporate@oncodna.com
Enterprise